Analytical Data
-
Gene name
UBE3A
- Application
-
Alternative Names
Oncogenic protein-associated protein E6-AP
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O08759
-
Expression Region
542-870aa
-
Molecular Weight
41.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UBE3A, also known as ubiquitin-protein ligase E3A, is a crucial protein implicated in regulating protein degradation through the ubiquitin-proteasome pathway. Its research is particularly significant in the context of Angelman syndrome, a neurodevelopmental disorder caused by the loss of function of the UBE3A gene, primarily inherited from the mother. In neurons, UBE3A is subject to genomic imprinting, which means that the paternal allele is typically silenced, leading to the manifestation of symptoms when the maternal allele is mutated or deleted. This unique mechanism has made UBE3A a focal point for understanding not only Angelman syndrome but also broader implications in neurodevelopmental disorders and brain function. Researchers have been exploring the structure and function of UBE3A, aiming to elucidate its role in synaptic regulation, learning, and memory. Recent advances in gene editing technologies, such as CRISPR/Cas9, have opened new avenues for potential therapeutic interventions, including the reactivation of the paternal UBE3A allele. By generating recombinant UBE3A proteins, scientists are investigating their interactions, post-translational modifications, and overall impact on neuronal health. Overall, UBE3A research is critical for uncovering the underlying mechanisms of Angelman syndrome and developing targeted therapies to alleviate its effects, ultimately contributing to our understanding of neurodevelopmental conditions and their treatment.
